BrainStorm Cell Therapeutics Inc. (BCLI) stock
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
Earnings
BrainStorm Cell Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of BrainStorm Cell Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 13, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 14, 2026during market hours | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 15, 2026during market hours | – | – | -$0.19 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 31, 2026during market hours | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 14, 2025during market hours | – | – | -$0.19 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025before the open | – | – | -$0.34 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 15, 2025during market hours | – | – | -$0.45 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 31, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024during market hours | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 14, 2024before the open | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 1, 2024before the open | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Apr 1, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023before the open | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023before the open | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023before the open | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 30, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022before the open | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022before the open | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022before the open | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 28, 2022before the open | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 26, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 4, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 15, 2020before the open | – | – | – | Filing |
| Q2 FY2016ended Jun 30, 2016 | Aug 11, 2016before the open | – | – | – | Filing |
| Q1 FY2016ended Mar 31, 2016 | May 10, 2016during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
BrainStorm Cell Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When BrainStorm Cell Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases BrainStorm Cell Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- News
- News
- Results
- Results
- Results
- Update
- Results
- News
See a number that looks wrong?